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8.1 Introduction
CRLX101 (formerly IT-101) is a novel cyclodextrin-based polymer that self-
assembles into nanoparticles. CRLX101 was designed to deliver sustained
levels of the cytotoxic agent camptothecin (CPT) to tumour cells while
minimizing delivery to normal tissue. Covalent conjugation of hydrophobic
CPT to the cyclodextrin polymer increases its water solubility by three orders
of magnitude and prevents inactivation through spontaneous lactone ring
opening, a process that occurs rapidly at physiologic pH.1
CPT derivatives such as irinotecan (CPT-11, Camptosars; Pfizer) and
topotecan (TPT, Hycamtins; GlaxoSmithKline) demonstrate clinical utility
for the treatment of advanced solid tumours. The primary cellular target of
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CPT is the topoisomerase-1 (TOP1)–DNA cleavage complex which, when
stabilised, prevents TOP1-mediated unwinding and subsequent DNA repair.
Exposure of cancer cells to CPT leads to replication-mediated accumulation
of double-stranded DNA breaks and apoptosis. However, the interaction of
CPT with DNA is non-covalent and reverses within minutes of drug removal.2
More recently, CPT and prolonged low-dose TPT have been shown to down-
regulate hypoxia-inducible factor 1 (HIF-1a), which is associated with angio-
genesis, metastasis, and resistance to vascular endothelial growth factor
(VEGF) inhibition. Both mechanisms of action have important pharmaco-
logical implications that favour sustained exposure of tumours to active
concentrations of these compounds.3 However, CPT derivatives are associated
with considerable toxicity, including diarrhoea and myelosuppression.4,5
In preclinical studies, CRLX101 nanoparticles demonstrated reduced
rapid renal clearance compared to CPT, resulting in a prolonged plasma
half-life compared to small-molecule CPT analogues. Furthermore, in
tumour xenograft models, CRLX101 accumulated preferentially in tumour
tissue because of the enhanced permeability of tumour neo-vasculature
(Figure 8.1). Notably, prolonged release of active CPT from CRLX101 nano-
particles has been observed in tumour tissue resulting in enhanced TOP1
inhibition, potential HIF-1a eﬀect, and increased antitumour activity against
multiple human tumour xenografts (e.g. lymphoma, breast cancer, ovarian
cancer, lung cancer, and colon cancer) compared to CPT-11 and TPT.6,7
In the first-in-human phase I clinical trial of CRLX101 that was designed
to determine the toxicity, safety profile, and pharmacokinetics of CRLX101,
the maximally tolerated dose (MTD) was determined and recommended to
test in phase II studies with a weekly or bi-weekly dosing schedule.8
In this chapter, we try to position CRLX101 among relevant CPT polymeric
nanoparticles and compare their mechanisms of action, chemical and
physical properties and physiological outcomes. Thus, the first three
sections cover a wide range of nanotherapeutic strategies to target TOP1,
HIF-1a, and cancer stem cells. In the fourth section, we highlight the value of
combining antiangiogenics with HIF-1a inhibitors. Finally, we cover in detail
the preclinical and clinical evaluations of CRLX101 and discuss future
directions.
8.2 Topoisomerase 1 Inhibitors
CPT was first semi-synthesised from the Chinese tree, Camptotheca acumi-
nata in 1966.9 CPT is a potent alkaloid cytotoxic agent that inhibits TOP1
enzymatic activity, blocks cell cycle during the S-phase and induces cellular
apoptotic death. Under physiological conditions, TOP1 cuts one DNA strand,
allowing the DNA to uncoil, and then re-ligates the DNA back into its super-
coiled form. However, when CPT is present, it binds to the TOP1–DNA
complex and prevents the re-ligation of the DNA, which eventually leads to
apoptosis. CPT has low aqueous solubility in the lactone form and can be
highly toxic in its carboxylate form.10 In 1972, a phase II clinical study from
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the Mayo Clinic evaluated the sodium carboxylate form of CPT in 61
patients, and objective responses after 2 months were observed in only two
(3%) patients with advanced gastrointestinal cancer. CPT was administered
intravenously at a dose range of 90–180mg m2 every 21 days. The dose-
limiting toxicity was reversible bone marrow suppression (leukopaenia
and thrombocytopaenia). Other toxic eﬀects included nausea, vomiting,
diarrhoea, stomatitis, dermatitis, alopecia, and haemorrhagic cystitis. Based
on the high degree of toxicity and the low response rate, further clinical
evaluation of CPT was discontinued.11
Hertzberg et al.12 synthesized several CPT derivatives in which the hydroxy
lactone ring was modified and evaluated for inhibition of TOP1 and
cytotoxicity to mammalian cells. The hydroxy lactone ring of CPT was critical
for in vivo antitumour activity, consistent with earlier results, and correlated
with the structure–activity relationships of TOP1 inhibition. Thus, in retro-
spect, it is not surprising that all prior clinical trials of CPT, in which the
soluble, open ring sodium carboxylate form of CPT (i.e. lacking the hydroxy
Figure 8.1 CRLX101-mediated dynamic tumour targeting. CRLX101 nanoparticles
target tumours via leaky vasculature and releases their camptothecin
(CPT) payload within tumour cells. This results in profound pharmaco-
kinetic improvement, a sustained drug exposure and low systemic
distribution.
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lactone ring) was administered, resulted in poor clinical outcome.12 A
biochemical study demonstrated in 1994 that human serum albumin
preferentially binds the carboxylate of CPT with a 150-fold higher aﬃnity
than the lactone form. As a result of this interaction, the lactone ring opens
rapidly and fully to the carboxylate form in human plasma under physio-
logical conditions. Because earlier studies have shown that the carboxylate
form of CPT is clinically inactive, even dosing the active form of CPT (which
was not done in the earlier clinical trials) would not have resulted in clinical
activity, because CPT would have been rapidly converted to the inactive form
upon dosing. Thus, lactone ring stabilization is required to obtain mean-
ingful clinical activity.13
Several studies attempted to modify CPT chemical structure in order
to lower its toxicity profile and increase its water solubility. Most notably,
CPT-11 and TPT are two examples of CPT chemically modified to keep
lactone stability and increase water solubility. CPT-11 is a prodrug that is
enzymatically converted into active 7-ethyl-10-hydroxy-CPT (SN38), which
is 100–1000 times more potent but less water soluble. In Japan, the use of
CPT-11 was approved for small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC), cervical cancer, and ovarian cancer. In Europe, the use
CPT-11 was approved for second-line monotherapy and combination with
fluoropyrimidines in patients with colon cancer. In the USA, TPT was
approved for use in patients with second-line ovarian cancer and SCLC.14
Water-soluble 7-modified CPT, gimatecan (ST1481) is another example that
has been tested in a panel of diﬀerent tumour types including platinum-
resistant cancer cells. Compared to TPT, gimatecan showed superior anti-
proliferative activity against many cancer types, except for glioma.15 In 2008,
Franco Zunino and his group at the IRCCS Foundation National Cancer
Institute in Milan, Italy synthesised a novel hydrophilic CPT analogue with
anti-tumour features, ST1968. To increase CPT solubility, ST1968 was
synthesised by oxyiminomethylation on position 7 of CPT. Although ST1968
is less potent than other CPT derivatives such as active SN38, it showed
remarkable activity against CPT-11-resistant tumour models and yeast cells
transfected with mutant TOP1.16 In 2008, another study from the same
group identified a novel TOP1 inhibitor, topopyrone C, isolated from the
fungi Phoma and Penicillium and successfully synthesized and modified it
in vitro.17,18 Cananzi et al. described in 2011 a novel analogue of lamellarin D
that inhibited TOP1 and exhibited anti-tumour activity against NSCLC
cells.19 Recently, Cincinelli et al. synthesized a novel hybrid CPT-platinum
anticancer agent. 7-oxyiminomethyl CPT was linked to diaminedichloro-
platinum and tested for activity against a panel of cancer cells including
TPT- and platinum-resistant types. In vivo studies on H460 human NSCLC
xenografts showed 82% tumour volume inhibition. This hybrid agent was
well tolerated at higher doses than those established for cisplatin but at
lower doses than those established for CPT-11.20
Novel strategies to modify CPT water solubility and lower its toxicity also
include the use of polymeric nanoparticles. In order to achieve a successful
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nanotherapeutic approach, three criteria have been suggested. (1) Nano-
particles must evade immunorecognition. For example, some approaches
use polyethylene glycol (PEG) to mask nanoparticles from the immune
system. (2) Nanoparticles must be eliminated after the biological eﬀect has
occurred. For instance, biodegradable materials can be used to control
cellular uptake and the release rate of the free drug. (3) Nanoparticles must
be delivered and accumulated preferentially in target tissue.21 Besides active
targeting that involves certain molecules with specific aﬃnity to tumours,
high molecular weight nanoparticles can passively accumulates in tumour
tissue due to an enhanced permeation and retention (EPR) eﬀect, and this
accumulation can be sustained for a substantial amount of time since
tumour tissues severely lack functional lymphatic vasculature.22
8.2.1 Carbohydrate-based Polymeric Nanoparticles
Mersana Therapeutics developed a carbohydrate-derived polymeric nano-
particle called XMT-1001, which uses a 40–70 kDa biodegradable hydrophilic
polyacetal, poly(1-hydroxymethylethylene hydroxymethylformal) ‘‘Fleximer’’
conjugate to increase the solubility of CPT. XMT-1001 loaded with 7.5 wt%
CPT showed improved antineoplastic eﬃcacy against LS174T human colon
tumour and A2780 human ovarian tumour xenografts in mice. Although
accumulation in tumour tissue was detected, most carrier nanoparticles
remained in circulation and free CPT levels were substantially high in liver
tissue.23 In a dose-escalation phase I study of 49 patients with advanced solid
tumours (ClinicalTrials.gov identifier NCT00455052), intravenous adminis-
tration of XMT-1001 at a dose range of 1–85mg m2 of CPT equivalent
showed favourable pharmacokinetics with sustained free CPT plasma levels
beyond 24 hours post-administration. Although no haemorrhagic cystitis
or diarrhoea was detected, the highest dose caused grade 3 and grade 4
neutropaenia in two patients. 12 patients with refractory tumours had stable
disease for more than 12 weeks, most of whom had pancreatic or NSCLC.24
Ochi and colleagues at Daiichi Sankyo Company (Japan) described a
novel CPT-analogue nanoparticle DE-310 with potent antitumour activity.
DE-310 is a carboxymethyldextran polyalcohol (CM-Dex-PA)—a class of
polyhydroxylated carboxymethylpolysaccharides, which is linked to a hexa-
cyclic CPT-derivative compound called DX-8951 monomethanesulfonate
dehydrate (DX-8951f, also known as exatecan). In the nanoparticle, exatecan
payload was linked via a Gly-Gly-Phe-Gly tetrapeptide spacer and achieved a
loading capacity of 5–7 wt%. The DE-310 nanoparticle has a relatively large
molecular size (360 kDa) and thus could passively target tumour tissue
through the EPR eﬀect and eﬃciently delay renal filtration. In a murine
malignant fibrosarcoma ascites model, DE-310 showed prolonged survival
up to 300% and free DX-8951 could be detected in both serum and ascites
fluid. DE-310 seemed to be preferentially taken up by tumour cells than
macrophages nearby. One possible explanation for this is the nanoparticle’s
high hydrophilicity, which could have caused decreased endocytic response
Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101 203
D
ow
nl
oa
de
d 
by
 C
al
ifo
rn
ia
 In
sti
tu
te
 o
f T
ec
hn
ol
og
y 
on
 2
9/
07
/2
01
6 
18
:4
9:
31
. 
Pu
bl
ish
ed
 o
n 
31
 M
ar
ch
 2
01
6 
on
 h
ttp
://
pu
bs
.rs
c.o
rg
 | d
oi:
10.
103
9/9
781
782
622
53
6-0
019
9
View Online
of macrophages. The rationale for using the Gly-Gly-Phe-Gly spacer in
DE-310 was to provide a sustained release of DX-8951 at a slow rate into the
tumour tissue without prematurely releasing the drug into the peripheral
circulation. Gly-Gly-Phe-Gly tetrapeptide is predominantly cleaved by
cysteine proteases, which are reportedly overexpressed in a wide range of
malignant tumours, including colon cancer (cathepsin H), metastatic bone
marrow tumours (cathepsin L), and many other malignant tumour types
(cathepsin B). Hence, once DE-310 is endocytosed by tumour cells,
proteolytic lysosomal activity releases the free drug.25,26
T-0128 (MEN4901; Tanabe Seiyaku, Japan) is a 130 kDa polymeric nano-
particle conjugate of a novel CPT analogue (7-ethyl-10-aminopropyloxy-CPT
or T-2513) to carboxymethyl dextran (CM-Dex). Unlike DE-310, this non-
PA-polysaccharide nanoparticle’s Gly-Gly-Gly linker allowed T-0128 to be
preferentially taken up by macrophages or macrophage-like tumour cells.
Tumour-associated cathepsins were shown to be responsible for the lyso-
somal drug release.27 In vitro studies showed that T-0128 did not accumulate
in malignant tumour cells including highly refractory Walker-256 rat
carcinoma and B16 melanoma cells, while macrophage-like cells, such
as J774.1, internalized T-0128 very eﬃciently. Fluorescein isothiocyanate
dextran uptake suggested that T-0128 was possibly taken up by macrophages
through fluid-phase pinocytosis.28 Surprisingly, other studies showed that
intravenous administration of T-0128 in several xenograft models including
Walker-256 carcinoma, MX-1 mammary carcinoma, LX-1 lung carcinoma,
St-4 gastric, and HT-29 colorectal tumours showed prolonged survival and
tumour growth delay, many of which are highly refractory to CPT-11 and
TPT.29 Pharmacokinetic studies demonstrated that T-0128 could achieve
relatively long plasma half-life and eﬃcient tumour targeting. Nevertheless,
substantial amounts of T-0128 nanoparticles were taken up by hepatic and
splenic tissue and could potentially cause severe toxicities.30
8.2.2 Polyamine Polymeric Nanoparticles
Developed by Cell Therapeutics (Seattle, WA, USA), CT-2106 is a poly(L-
glutamic acid) conjugate to 20(S)-camptothecin (PG-CPT). The 20(S)-hydroxyl
group of CPT is linked to multiple g-carboxylate sites on the PG polymer.
Using a glycine linker, CPT loading on the polymer achieved up to 50 wt%.
The high molecular weight of the PG anionic polymer not only increased
CPT solubility, but also improved tumour penetration through the EPR eﬀect
and enhanced tumour growth inhibition compared to free CPT. Another
feature of PG-CPT is its biodegradability which allows for the slow release of
active CPT from nanoparticles once they are endocytosed by target cells.31
Preclinically, CT-2106 showed potent antitumour activity against a drug-
resistant human NSCLC cell line. Intravenous injection resulted in delayed
tumour growth and prolonged median overall survival (mOS) up to four-fold
in a nude mouse xenograft model. Additionally, CT-2106 showed favourable
pharmacokinetics and a slow CPT release rate (1% per day) under pH-neutral
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conditions.32 In 2003, phase I studies of CT-2106 in patients with advanced
solid tumours were conducted (ClinicalTrials.gov identifier NCT00059917).
Endpoints were to determine the MTD, toxicity, pharmacokinetics, and
response rate of CT-2106. Patients with melanoma were the predominant
population in the study. Fewer than 20% of patients had haematology-
related toxicities (mostly anaemia). Although the study showed favourable
pharmacokinetics and slower urinary excretion, no objective response
(neither partial nor complete) was observed.33 In 2006, CT-2106 entered
phase II clinical trials for the second-line treatment of ovarian cancer.
Primary endpoints were to measure response rate and secondary measure-
ments were of toxicity, response duration, time to progression (TTP), and
survival (ClinicalTrials.gov identifier NCT00291837).
Dallavalle et al. described in 2006 the synthesis of a series of novel
CPT-conjugates with a polyamine chain linked to position 7 of CPT via an
iminomethyl group. The compounds showed TOP1 inhibition and antitumour
activity against H460 human NSCLC cells. Moreover, polyamine conjugation
to CPT enhanced its solubility and tumour growth inhibitor eﬀects.34
Dal Pozzo et al. designed novel tumour-targeted RGD (Arg-Gly-Asp)
peptide–camptothecin conjugates. RGD cyclopeptides showed high aﬃnity
to aV integrin receptors, which are preferentially overexpressed in tumour
cells. By conjugating RGD cyclopeptides to CPT, selective tumour tissue
targeting could be anticipated, and thus toxicity reduced. In fact, RGD
peptide–CPT conjugates showed high aﬃnity to integrin aV and internalised
into tumour cells overexpressing integrin aV [A498 renal cell carcinoma (RCC)
and A2780 ovarian carcinoma], but not tumour cells with low levels of integrins
(PC3 prostate carcinoma). Moreover, tumour cells slowly internalised RGD
peptide–CPT resulting in improved drug accumulation compared to free CPT
treatment. In an A2780 human ovarian carcinoma xenograft model, RGD
peptide–CPT conjugates were injected intraperitoneally or subcutaneously,
resulting in 40% tumour growth inhibition and well-tolerated toxicities at a
dose of 48mgkg1. Free-drug release rate in blood circulation wasB2.5% and
high levels of conjugate were detected inside tumours.35
8.2.3 HPMA Copolymeric Nanoparticles
HPMA copolymeric nanoparticles have been used to conjugate several
cytotoxic drugs including paclitaxel (PNU166945), CPT (PNU166148 or
MAG-CPT) and two platinates [AP5280 and AP5346 (ProLindac)].36 All these
nanoparticles share a common N-(2-hydroxypropyl)methacrylamide (HPMA)
copolymer core. PNU166148 was developed by Pharmacia using HPMA and
methacryloyl-glycine-ONp 95 : 5 or 90 : 10, thus the acronym MAG-CPT. CPT
was modified at C-20 a-hydroxy group with glycine, which could be hydro-
lysed by esterase during endocytosis. In order to conjugate HPMA to CPT, a
tetrapeptide (Gly-Phe-Leu-Gly) linker was attached, which provided both
lactone ring stability in blood circulation and enhanced lysosome-mediated
release of free CPT inside cells. Depending on its formulation, MAG-CPT had
Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101 205
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molecular weight of 20.9–27.8 kDa and CPT loading capacity of 5–10 wt%.
When mixed with plasma, MAG-CPT did not aggregate and its interaction
with serum albumin was weaker than that of free CPT.37,38 Pharmacokinetic
studies showed significant renal elimination of hydrolysed nanoparticles.
The MAG-CPT linker was later modified to Gly-C6-Gly and was selected for
dose-escalation phase I studies (ClinicalTrials.gov identifier NCT00004076).
The study included 23 patients who received an intravenous infusion over
30 min every 4 weeks. The reported recommended MTD was 200mg m2,
and dose-limiting toxicities included grade 4 neutropaenia and thrombocy-
topaenia and grade 3 diarrhoea, and severe and unpredictable cystitis was
also observed in few patients. The most pronounced adverse eﬀect was
bladder toxicity (dysuria and microscopic and macroscopic haematuria) and
could only be resolved by withdrawal of treatment. One treatment-associated
death was also reported. Moreover, no objective clinical responses were
observed. Due to the severe bladder toxicities associated with MAG-CPT, new
formulations attempted to decrease the polymer molecular weight in order
to enhance urinary excretion. However, this new formula also meant that
free CPT levels became lower in the tumour (12.2 ng g1) compared to the
normal tissue (21.9 ng g1). Based on these results, clinical development of
MAG-CPT was terminated.39,40
8.2.4 PEG Polymeric Nanoparticles
The use of PEG in drug delivery dates back to the 1970s. In theory, attaching
PEG chains to the drug molecule of interest could achieve improved drug
solubility, reduced dosage frequency, reduced toxicity, extended circulating
life, increased drug stability, and enhanced protection from proteolytic
degradation.41,42
Prothecan is a CPT-conjugated polymeric nanoparticle that was developed
by Enzon Pharmaceuticals (Plantation, FL, USA) and entered phase II studies
in patients with SCLC. In 1996, Greenwald et al. conceptualized the
importance of increasing water solubility of CPT by conjugating it to PEG in
a similar manner to that previously described for paclitaxel. Using an
alanine linker, CPT could be conjugated to PEG giving a molecular weight of
40 kDa and dramatically improved solubility (2mgmL1 in water compared
with 0.0025mgmL1 free CPT in water). Superior eﬃcacy against P388
murine leukaemia and HT-29 human colorectal xenograft models and
favourable pharmacokinetics ultimately led to choosing prothecan for phase
I clinical studies in patients with solid tumours. Single doses of as much as
7000mg m2 could be well tolerated and major toxicities were restricted to
neutropaenia and leukopaenia. Five out of 14 patients (35.7%) exhibited
stable disease and one patient (7%) had a partial response.43–45
Enzon’s second generation PEGylated CPT, pegamotecan, was developed
few years later. Pegamotecan used an alanitate ester to link the hydrophobic
CPT to hydrophilic PEG. Preclinical investigations showed superior anti-
tumour activity in a human colon cancer xenograft model. Green fluorescent
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protein-labelled PEG polymers were used to study biodistribution. As ex-
pected, high molecular weight PEG passively accumulated in tumour tissue
through the EPR eﬀect and induced apoptosis in cancer cells. Importantly,
liver and kidney toxicities were minimal compared to free CPT. Change in
expression of BAX and Bcl-2, tumour-associated pro- and anti-apoptotic
factors, indicated that caspase-dependent apoptotic pathways were respon-
sible for pegamotecan cytotoxicity.46 To determine the MTD and dose-
limiting toxicity of pegamotecan, a phase I dose-escalation study was
conducted in 27 patients with advanced solid tumours (ClinicalTrials.gov
identifier NCT00080002). At the highest administrated dose (4300mg m2),
one patient had grade 4 gastrointestinal haemorrhage, grade 4 neutropaenia,
and grade 3 haematuria and died 4 days later. Additional dose-limiting
toxicities included grade 3 toxicities including anaemia, thrombocytopaenia,
fatigue, prolonged partial thromboplastic time, haemorrhagic cystitis, dysuria,
and urinary frequency in two out of four patients. Haematuria also occurred in
eight out of 15 patients at a range of doses. Terminal elimination half-life was
at 46 12.8 hours and theMTD was determined to be 3240mgm2 every week
for 3–4 weeks. No confirmed objective responses were detected. Due to the
unanticipated high toxicity, a previously published dosing schedule with
subjects receiving a higher dose in longer cycles (7000mg m2 every 3 weeks)
was advanced instead.45 In 2009, phase II study results of second-line pega-
motecan monotherapy in patients with advanced and metastatic gastric
and gastro-oesophageal junction adenocarcinoma were published. Of the
34 patients who received the recommended dose, the partial response rate was
14.3% with a median TTP of 11.9 weeks and mOS at 38.1 weeks. Reported
grade 3/4 toxicities included neutropaenia, thrombocytopaenia, fatigue,
nausea, vomiting, and anorexia. Compared to CPT-11, pegamotecan had
favourable pharmacokinetic and toxicity profiles, which made pegamotecan a
good candidate for combination therapy. Although no drug-related mortality
was reported in this study, genitourinary toxicities persisted in 35% of patients
and microscopic haematuria was observed in 14.2% of patients.47 In 2004, a
safety and eﬃcacy phase II study (ClinicalTrials.gov identifier NCT00079950)
was conducted in patients with advanced or metastatic soft tissue.
Enzon also developed a PEG-prodrug that is loaded with SN38 (EZN-2208).
Since only 3–4% of an injected dose of CPT-11 is converted to SN38 in the
liver, and 55% of unconverted CPT-11 is excreted through renal clearance, it
has been hypothesized that PEG conjugation would protect the active SN38
and oﬀer antitumour features superior to CPT-11. Preclinical studies showed
that EZN-2208 was active against several in vivo tumour models that are
resistant to CPT-11 and showed prolonged circulation in the blood and thus
longer tumour exposure compared to the free drug.48,49 Moreover, EZN-2208
exhibited antitumour activity against TPT-resistant malignant tumours.50
A dose-escalation phase I study was conducted to evaluate the safety,
tolerability, pharmacokinetics, and activity of EZN-2208 in 39 patients with
advanced malignancies (ClinicalTrials.gov identifiers NCT00520637 and
NCT00520390). The nanoparticle was infused with or without granulocyte
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colony-stimulating factor (G-CSF) for 1 hour once every 21 days. MTD was
determined at 16.5mg m2 with G-CSF infusion and 10mg m2 without.
EZN-2208 was well tolerated and the dose-limiting toxicity was febrile neu-
tropaenia. Adverse eﬀects included fatigue (41%), alopecia (33%), diarrhoea
(33%), nausea (33%), neutropaenia (23%), and vomiting (21%). The nano-
particle achieveda terminalhalf-life of 19.4 3.4hours. Sixteenpatients (41%)
achieved stable diesease, including 15% in whom disease was stable for more
than 4 months.51 Subsequently, a multiarm phase II clinical study has been
conducted in second-line treatment of metastatic colon cancer (Clinical-
Trials.gov identifier NCT00931840). The first arm was infused with EZN-2208
alone (9mg m2 on days 1, 8 and 15 every 28 days) in 93 patients with KRAS-
mutation. The second and third arms included patients with KRAS wild-type
tumour randomised to receive 400mg m2 cetuximab (Erbituxs; Bristol-
Myers Squibb/Lilly/Merck) in combinationwith either 9mgm2 EZN-2208 (80
patients) or 125mg m2 CPT-11 (38 patients). In the KRAS-mutation arm, re-
sponse rate was 0% andmedian progression-free survival (mPFS) was only 1.8
months. In the KRAS-wild-type arms, cetuximab plus CPT-11 or EZN-2208
showedno significant diﬀerence in response rate (10.7% vs. 14.3%),mPFS (4.9
months vs. 3.7months)ormOS (9.1months vs. 9.8months). EZN-2208waswell
tolerated in combination with cetuximab. Grade 3/4 adverse events included
neutropaenia (30% in EZN-2208 alone, 35% in cetuximab plus EZN-2208, and
16% in cetuximab plus CPT-11); anaemia (10% in EZN-2208 alone, 1% in
cetuximab plus EZN-2208, and 13% in cetuximab plus CPT-11); leukopaenia
(8% in EZN-2208 alon, 9% in cetuximab plus EZN-2208, and 0% in cetuximab
plus CPT-11); and other non-haematological adverse eﬀects.52 Another phase
II clinical study has been conducted using EZN-2208 in patients with meta-
static breast cancer (ClinicalTrials.gov identifier NCT01036113).
Developed by Nektar Therapeutics, NKTR-102 (etirinotecan pegol) is a
polymeric nanoparticle with a proprietary PEG core conjugated to CPT-11 by
a biodegradable linker that is slowly hydrolysed to form active SN38. This
allows for a continuous exposure to SN38 and thus a prolonged TOP1
inhibition. NKTR-102 entered phase II clinical studies for colorectal cancer,
breast cancer, ovarian cancer, and cervical cancer. Awada et al. at the Jules
Bordet Institute, Universite´ Libre de Bruxelles (Brussels, Belgium) recently
reviewed results from a randomised phase II study of NKTR-102 in patients
with second-line metastatic breast cancer (ClinicalTrials.gov identifier
NCT00802945). The study included 70 patients randomly divided into two
equal groups, where two dosage schedules (145mg m2 every 14 days or
21 days) were chosen for treatment. Although results indicated that 29% of
patients achieved an objective response, grade 3 or worse adverse events
were reported. On the 14-day dosing schedule, drug-related toxicities led to
the discontinuation of 20% of subjects and caused two possible drug-related
deaths (renal failure and septic shock). Therefore, the less toxic 21-day
schedule was chosen instead for a subsequent phase III trial in 840 patients
with metastatic breast cancer who previously received an anthracycline,
a taxane and capecitabine (Xelodas; Roche) (BEACON trial,
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ClinicalTrials.gov identifier NCT01492101). This phase III has completed and
the clinical data did not demonstrate an improvement in overall survival for
etirinotecan pegol compared with treatment of physician’s choice in patients
with pre-treated breast cancer.53–55,151 Vergote et al. recently published re-
sults from a phase II clinical trial of NKTR-102 in patients with recurrent
platinum-resistant/refractory epithelial ovarian cancer (ClinicalTrials.gov
identifier NCT00806156). Two dosage schedules (145mgm2 every 14 days or
21 days) were given to 71 eligible patients divided into two groups. The overall
response rates (ORR) were 20% and 19%; mPFS was 4.1 months and
5.3 months, and mOS was 10.0 months and 11.7 months for the 14-day and
21-day schedules, respectively). Grade 3/4 toxicities included dehydration
(24%) and diarrhoea (23%), whereas neutropaenia was less frequent
(11.3%).56 On a side note, the study suggested the use of the TOP1 gene as a
biomarker prior to treatment in order to predict sensitively and reduce po-
tential toxicities.53 Other NKTR-102 clinical studies include an open-label
multicenter extension study of NKTR-102 in subjects previously enrolled
in NKTR-102 studies (ClinicalTrials.gov identifier NCT01457118); a phase
IIa/IIb multicenter open-label study to evaluate NKTR-102 in combination
with cetuximab vs. irinotecan in combination with cetuximab in second-line
colorectal cancer patients (ClinicalTrials.gov identifier NCT00598975); a
phase II study in cancer patients with hepatic impairment to evaluate the
pharmacokinetics and safety of NKTR-102 (ClinicalTrials.gov identifier
NCT01991678); a phase I study of NKTR-102 in bevacizumab-resistant high
grade glioma (ClinicalTrials.gov identifier NCT01663012); a phase II study
in patients with relapsed SCLC (ClinicalTrials.gov identifier NCT01876446); a
new phase II study in patients with second-line, irinotecan-naı¨ve, KRAS-
mutant colorectal cancer (ClinicalTrials.gov identifier NCT00856375); and a
phase II study in NSCLC (ClinicalTrials.gov identifier NCT01773109).
Other polymeric nanoparticle approaches include CPT-loaded poly-
(DL-lactic acid) and poly(ethylene glycol)-block-poly(propylene glycol)-block-
poly(ethylene glycol) copolymer (PEG-PPG-PEG), which has been shown to
enhance the anti-tumour eﬃcacy of CPT.57
8.2.5 Amphiphilic Polymeric Nanoparticles
In 2004, Zhang et al. at Nanjing University in China described a new
family of biodegradable copolymers called poly(caprolactone-co-lactide)-b-
PEG-b-poly(caprolactone-co-lactide) or PCLLA-PEG-PCLLA. This amphiphilic
copolymer self-assembles into 70–180 nm nanoparticles that encapsulate a
new CPT derivative 10-hydroxycamptothecin-10,20-diisobutyl dicarbonate or
HCPT-1. Depending on copolymer composition and preparation conditions,
HCPT-1 loading could achieve up to 7 wt% and water solubility increased
3000 times compared to the free drug. When dispersed in PBS, free HCPT-1
was rapidly released (up to 30% was released in the first hour). After 8 hours,
HCPT-1 release steadily slowed down. The fast release could be due to the
large surface area of the nanoparticle or the low Tg of the hydrophobic core
Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101 209
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of PCLLA-PEG-PCLLA nanoparticles, causing high mobilization of HCPT-1.
However, biodistribution analysis showed that HCPT-1 blood concentration
was relatively stable after 24 hours of intravenous injection. The highest
levels of HCPT-1 accumulation were detected in mouse lung and spleen
tissue and low levels were also detected in the kidney and liver. More pre-
clinical studies are needed to verify the pharmacodynamics of this drug.58,59
Another interesting approach was taken by a 2010 Korean study at Kyung
Hee University using pH-sensitive amphiphilic nanoparticles to encapsulate
CPT. The pH-responsive polymeric micelle consisted of hydrophilic methyl
ether PEG and pH-responsive poly(b-amino ester) that copolymerized,
self-assembled and encapsulated CPT at neutral conditions (pH 7.4). The
nano-sized (214 nm) particle depolymerizes in response to the tumoural
acidic conditions (pH 6.4). Amphiphilic nanoparticles with an optimal drug
loading of 10 wt% were shown to passively target breast tumour xenografts
and release CPT load in response to a slightly acidic microenvironment.
Importantly, antitumour activity was detected and 470% of CPT in the
lactone ring form could be maintained for 24 hours. Using fluorescence
imaging, the pH-PM biodistribution result clearly showed substantial
tumour accumulation and an overall favourable pharmacokinetic profile.60
8.2.6 Bioconjugates
Minko et al. at Rutgers (USA) studied the cytotoxicity and antitumour eﬃcacy
of biotinylated PEG-conjugates to CPT. Biotin was included as a moiety to
increase intestinal absorption via sodium-dependent multivitamin trans-
porters. In this way CPT cytotoxicity increased up to 60 times in sensitive
A2780 and 30 times in A2780/AD multidrug-resistant ovarian cancer cells.
In vitro toxicity studies showed that PEG–biotin alone did not cause any cell
toxicity and CPT–PEG–biotin induced caspase-dependent apoptosis.61
Another novel bioconjugate was described in 2004 used a PEG backbone
conjugated to CPT via a glycine linker, and to folic acid via either of its two
available carboxylate groups on the distal end. This double conjugation
served two purposes. First, CPT water solubility was enhanced without
destabilizing its lactone structure. Second, the folic acid could hence
mediate tumour-specific endocytosis through the folate receptor, which is
overexpressed in human nasopharyngeal carcinoma, for example. Unlike
large nanoparticles, the CPT-Gly-PEG-folate conjugate has low molecular
weight and thus less immunogenic.62
Another CPT-bioconjugate approach used substance P, an 11-residue
neuropeptide, to conjugate to CPT to specifically target tumour cells that
overexpress neurokinin-1 receptor. This proof-of-concept approach showed
selective and strong cytotoxicity across many malignant tumour types,
including breast cancer, astrocytoma and glioblastoma. Since substance P is
a short peptide, it can be chemically synthesised. Another feature of sub-
stance P is that only C-terminal amino acids are essential for neurokinin-1
receptor-mediated binding and cellular internalization, while the N-terminal
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could be used for CPT conjugation. Similar to other linkers, cysteine amino
acid on the N-terminal allowed for proteolytic release of CPT, and amino-
hexanoic acid was used as a spacer to avoid steric hindrance. However, CPT
solubility improved only about 38 times, and when loading of CPT increased,
the conjugate solubility worsened. Moreover, both cellular internalization
and cytotoxicity could improve when a spacer was used. More preclinical
studies are needed to verify the pharmacokinetic and pharmacodynamic
feature of this novel drug. Moreover, new formulations should be used to
improve its stability, solubility, and cytotoxicity.63
Vekhoﬀ et al. described a new generation of CPT conjugates with
sequence-specific DNA ligands that enhanced CPT positioning to its binding
site on the DNA of target cells. This could be achieved by conjugating a
bromoalkyl analogue of gimatecan to the 30 end of triplex-forming oligo-
nucleotides (TFO). A TFO–gimatecan conjugate proved to be both stable and
potent against HeLa cells in vitro.64
Other bioconjugate approaches include hyaluronic acid-conjugated
CPT-11 (Meditech Research);65 transferrin–PEG nanoparticles;66 and camp-
tothecin coupled to bombesin analogue.67
8.2.7 Non-polymeric Nanoparticles
Non-polymeric nanoparticles are listed and reviewed elsewhere. They
include IHL-305 CPT-11 liposomes (Yakult Honsha, Japan);68 CPX-1
irinotecan-floxuridine liposome;69 STEALTH liposomal S-CKD-602;70 SN38
liposomes from Neopharm;71 and NK012 SN38 micelle.72
8.3 Hypoxia Inducible Factor-1 Inhibitors
HIF-1 is a transcription factor that plays an essential role in the cellular
hypoxic response. When activated, its two subunits, HIF-1a and HIF-1b,
dimerise and enhance the expression of survival genes.73 Genetic analysis
revealed that more than 60 putative genes could be direct targets of HIF-1
activation. These target genes fall largely into four categories: angiogenesis,
glycolysis, tumour survival, and invasion. Within hypoxic tumour tissue,
HIF-1 activation leads to the transcription of target genes responsible
for pathophysiological phenotypes such as immortalization, stem cell-like
features, dediﬀerentiation, neo-angiogenesis, invasion, and metastasis. In
cancer therapy, HIF-1a overexpression has been linked to antiangiogenic-
associated drug resistance and poor prognosis across several tumour types
including breast cancer, ovarian cancer, and gastric cancer.74–76 Moreover, an
important indicator of HIF-1 abnormal activity, carbonic anhydrase-IX (CAIX),
is up-regulated in many tumour types and linked to poor prognosis.77–82
8.3.1 2ME2
2-methoxyestradiol (2ME2; Panzem), is a microtubule polymerization
inhibitor that has been shown to interact with HIF-1a and block
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angiogenesis.83 In a phase II safety study of orally administrated 2ME2 in
patients with homrmone-refractory prostate cancer, the drug was well tol-
erated in general. However, since pharmacokinetic results also showed low
sustainability,84 2ME2 was reformulated as a NanoCrystals colloidal dis-
persion (NCD). In a phase II study of 2ME2 NCD in 21 patients with taxane-
refractory, metastatic castrate-resistant prostate cancer (ClinicalTrials.org
identifier NCT00394810), only 5.35% reached PFS at 6 months, while the
mPFS was 56 days and there was no objective response. Grade 3/4 adverse
events were observed in 33% of patients. However, compared to the free
drug, 2ME2 NCD showed favourable pharmacokinetics with 10–20 times
higher levels of 2ME2 and its metabolite 2ME1 in plasma.85 Additionally, a
multicenter phase II study was conducted (ClinicalTrials.org identifier
NCT00444314) of 2ME2 NCD alone with its combination with sunitinib
(Sutents; Pfizer) in second-line metastatic RCC. Only 12 patients were eva-
luable in the trial and the study was terminated due to the drug’s minimal
antitumour activity and high intolerability. New formulations are currently
under development.86 Other clinical trials with 2ME2 NCD include a phase II
study in combination of with bevacizumab (Avastins; Genentech/Roche) in
patients with metastatic carcinoid tumours (ClinicalTrials.org identifier
NCT00328497); a phase II study in patients with relapsed or plateau-phase
multiple myeloma (ClinicalTrials.org identifier NCT00592579); a phase II study
in patients with glioblastoma (ClinicalTrials.org identifier NCT00306618; a
phase II study in patients with ovarian cancer (ClinicalTrials.org identifier
NCT00400348); and a phase II study in combination with the chemother-
apeutic drug temozolomide (Temodars; Merck) in patients with recurrent
glioblastoma multiforme (ClinicalTrials.org identifier NCT00481455).
8.3.2 Camptothecins
CPT and TPT are also known to inhibit HIF-1a expression in addition to the
TOP1 inhibitory eﬀects described above. CPT derivatives inhibit HIF-1a
expression when administrated daily at low nanomolar concentrations.87
Additionally, the presence of CPT under hypoxic conditions have also been
shown to down-regulate VEGF expression.88
Little is known about how CPT inhibits HIF-1a. A recent paper by Giovanni
Capranico and colleagues at the University of Bologna (Italy), suggested a
molecular mechanism by which CPT inhibits HIF-1a activity.89 Using
microarray analysis, two micro-RNAs (miR-17-5p and miR-155) were identi-
fied as CPT-associated suppressors of HIF-1a protein expression. Moreover,
it has been suggested that TPT acts on HIF-1a through a signalling pathway
downstream of TOP1.87
Several clinical studies have been conducted to test the therapeutic
potential of using CPT derivatives to inhibit HIF-1 in tumour tissue. A phase I
study in which oral TPT was administrated in combination with radio-
therapy in patients with rectal cancer was conducted in September 2005
(ClinicalTrials.org identifier NCT00215956). A phase I pharmacokinetic
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study of weekly low doses of TPT administrated intravenously in combin-
ation with carboplatin and etoposide in patients with extensive stage SCLC
was conducted in August 2006 (ClinicalTrials.org identifier NCT00025272).90
Another phase I dose-escalation pharmacokinetic study of TPT in combin-
ation with erlotinib (Tarcevas; Genentech/Roche) in patients with refractory
solid tumours was conducted in January 2008 (ClinicalTrials.org identifier
NCT00611468).
8.3.3 siRNA Technologies
Using locked nucleic acid technology, Enzon Pharmaceuticals developed a
specific HIF-1a mRNA antagonist (EZN-2968) with durable and potent
antitumour eﬀects against human prostate and glioblastoma cell lines.91 A
phase I pilot study of EZN-2968 in patients with advanced solid tumours with
liver metastases has been conducted in order to determine the safety and
potency of EZN-2968 (ClinicalTrials.org identifier NCT01120288).
Liu et al. from the University of Science and Technology of China recently
developed a micellar nanoparticle containing HIF-1a short interfering
(si)RNA, which could block hypoxic tumour growth in prostate cancer
xenograft models.92
8.3.4 Endogenous HIF-1a Inhibitors
In addition to HIF-1a, two other family members (HIF-2a and HIF-3a) have
been identified which alternatively dimerise with HIF-1b and regulate the
hypoxic response.93,94 Other HIF-1a endogenous regulators include the von
Hippel–Lindau (VHL) tumour suppressor protein, which facilitates its
degradation through the ubiquitin pathway.95 Other endogenous inhibitors
of HIF-1a are listed in Bao et al.96 They include oxygen-sensitive factor-
inhibition HIF (FIH); p53; phosphatase and tensin homologue (PTEN) and
liver kinase B1 (LKB1). Recent studies showed the role of miRNAs in
regulating HIF-1a expression. miR-21 overexpression is associated with high
levels of HIF-1a and VEGF. Hypoxia leads to increased expression of miR-21
in pancreatic and prostate cancer cells. Knocking down miR-21 blocks VEGF
expression and the self-renewal capacity of cancer stem cells. miR-107
negatively regulates HIF-1a and VEGF expression under hypoxic conditions.
miR-210 up-regulates VEGF and CAIX in pancreatic cancer through HIF-1a.
miR-373 is positively associated with HIF-1a in hypoxic cells. miR-20 inhibits
VEGF and expression through HIF-1a in hypoxic breast cancer cells. miR-22
has anti-angiogenic eﬀects through down-regulation of HIF-1a and VEGF
expression in tumour tissue. miR-101 expression suppresses the self-renewal
capacity of cancer stem cells.96
8.3.5 Other HIF-1a Inhibitors
Due to the key role that HIF-1 seems to play in tumour progression, several
clinical and preclinical approaches have been taken to pharmaceutically
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modulate HIF-1 pathways or its upstream eﬀectors. Comprehensive reviews
of HIF-1 inhibitors can be found in Semenza74 and Xia et al.,97 but we list
some here. Developed by Bayer (Germany), BAY87-2243 is a potent HIF-1a
and HIF-2a inhibitor with antitumour activity.98 A phase I clinical study
conducted to evaluate the MTD of BAY87-2243 in patients with advanced
malignancies (ClinicalTrials.org identifier NCT01297530) was terminated due
to unanticipated high toxicities.99 Elara Pharmaceuticals (Germany) has de-
veloped ELR510444, which is a novel HIF-1a and HIF-2a inhibitor that reduced
RCC viability in a VHL-independent manner. ELR510444 induced necrosis,
apoptosis, and inhibited angiogenesis in 786-O and A498 RCC xenograft
models.100 Sorafenib (Bay4-9006, Nexavars; Bayer/Onyx) is a RAF kinase in-
hibitor that is approved for hepatocellular carcinoma, RCC, and thyroid cancer.
Studies also showed that sorafenib had inhibitory eﬀects on HIF-1 activ-
ity.101,102 Temsirolimus (CCI-779, Torisels; Pfizer) is anmTOR inhibitor that is
approved for RCC. Temsirolimus also inhibited HIF-1a in human lung cancer
cell lines under hypoxic conditions.103 A phase I/II clinical trial (Clinical-
Trials.gov identifier NCT00329719) is currently under way to evaluate the
synergistic eﬀects of combining temsirolimus with sorafenib. Geldanamycin,
an HSP-90-specific inhibitor, has been shown to promote HIF-1a degradation
under both hypoxic and normoxic conditions.104 Tanespimycin (17-AAG), a
derivative of geldanamycin with similar HIF-1a inhibitory properties is
currently being evaluated as both monotherapy and combination therapy with
anti-angiogenic agents in patients with multiple myeloma and breast cancer.105
Many other small molecules that target HIF-1a are currently tested pre-
clinically: the Trx-1 inhibitor PX-12 was reported to inhibit HIF-1 activity;106
PD98059 is an MEK inhibitor shown to inhibit HIF-1 activity preclinically;107
NSC-134754 is a novel small molecule that inhibits HIF-1a activity and
thus inhibits tumour progression.108,109 Other inhibitors include pleurotin
(1-methylpropyl 2-imidazolyl disulphide), a thioredoxin-1 inhibitor;106
YC-1 [3-(50-hydroxymethyl-20-furyl)-1-benzyl indazole], a synthetic compound
with HIF-1a-inhibitory activity;110,111 heteroarylsulfonamides (3,4-dimethoxy-
N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide), a
novel HIF-1a inhibitor tested against human glioma cells;112 and cyclic
peptide inhibitors of HIF-1.113
8.4 Cancer Stem Cells
The importance of targeting HIF-1 signalling pathways partly comes from
its role in regulating cancer stem cells and its role during epithelial-
mesenchymal transition. Although induced hypoxia has anti-tumour eﬀects,
it enhances the self-renewal capacity and maintenance of the dediﬀer-
entiated state of cancer stem cells. Surface marker studies confirmed that
hypoxia induces stem cell-like phenotypes and thus leads to tumour
aggressiveness and poor prognosis.96 Conversely, cancer stem cells use
induced hypoxia to protect from DNA damage by reduction of reactive
oxygen species. This can be achieved by activating HIF-1a, which is
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preferentially expressed in cancer stem cells compared with other cancer
cells in the same tissue. In vivo knockdown studies showed that both HIF-1a
and HIF-2a are required for cancer stem cell survival and tumour propa-
gation. In fact, knocking down these factors led to reduced tumour for-
mation or inhibited VEGF-mediated angiogenesis.114
Other evidence of the role of HIF-1 in cancer stem cell regulation is
covered in a review by Sarkar and colleagues at Wayne State University
(Detroit, MI, USA).96 In brief, activation of HIF-1 enhances the expression of
stem cell-associated genes such as Oct4, Nanog, c-Myc, Notch-1, and CD133
pathways. Moreover, factors downstream of HIF-1 such as CAIX can regulate
the acidic microenvironment of surrounding cancer stem cells. Clinically,
both HIF-1a and CAIX up-regulation have been associated with poor overall
and relapse-free survival.96
A paper by Wicha and colleagues at the University of Michigan
Comprehensive Cancer Center (Ann Arbor, MI, USA) demonstrated how
antiangiogenic therapy with either bevacizumab or sunitinib could increase
cancer stem cells in orthotropic breast xenograft models by making tumours
more hypoxic, thereby activating HIF-1a. These findings suggest that
combining antiangiogenic therapy with inhibitors of HIF-1a will be an
improvement over antiangiogenic therapy alone.115
Ambasta et al. described a novel technology that uses twin nanoparticles to
target both cancer stem cells and adjacent endothelial cells at the same time.116
8.5 Combination Therapy
VEGF overexpression under hypoxic conditions was first reported in 1992.117
A few years later, HIF-1 activation was linked to VEGF tumour pro-
gression.118,119 A recent review by Rapisarda and Melillo at the National
Cancer Institute (NCI; Bethesda, MD, USA) illustrated how combining anti-
angiogenic drugs with drugs that target HIF-1a is likely to be mechanistically
synergistic.120 Since anti-angiogenic treatment eventually induces hypoxia, it
will up-regulate HIF-1a, which in turn will promote tumour survival by
turning on pathways involving angiogenesis, cell metabolism, proliferation,
diﬀerentiation, and cancer invasion and metastasis. Therefore, VEGF
inhibitors undo their own eﬀects, so combining antiangiogenic therapy such
as bevacizumab with inhibitors of HIF-1a could have a synergistic eﬀect.
For example, a combination of bevacizumab with metronomic TPT over-
came the increase in hypoxia and HIF-1a induced by bevacizumab alone.
This strategy provided superior anti-angiogenic eﬀects, which also resulted
in superior anti-tumour activity in a glioblastoma xenograft model.3,121 An-
other remarkable preclinical study was performed by Kerbel and colleagues
at the University of Toronto. They demonstrated that combining pazopanib
(Votrients; GlaxoSmithKline), a VEGF receptor inhibitor, with metronomic
TPT, is synergistic and resulted in 100% survival of the drug combination
(but not the individual monotherapies) after 6 months of continuous
therapy in an aggressive, metastatic, orthotropic xenograft ovarian model.122
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Two orthotropic ovarian cancer model studies showed that combining
pazopanib with metronomic TPT is synergistic and resulted in a significant
improvement in survival vs. the individual monotherapies.123 Burkitt et al. at
the University of Michigan Comprehensive Cancer Center demonstrated that
genetic disruption of both HIF-1a and HIF-2a had synergistic anti-tumour
activity when combined with sunitinib in a colorectal xenograft model.124
Clinically, Kummar et al. at the NCI demonstrated that metronomic
dosing of TPT inhibited HIF-1a in patients, and that correlated with anti-
angiogenics as well, as measured by decreased tumour expression of VEGF
and decreased tumour blood flow and permeability. These data validate
extensive preclinical data showing that metronomic TOP1 inhibition can
inhibit HIF-1a and important downstream targets of HIF-1.125 Recently, a
multicenter phase II trial combining TPT with cisplatin and bevacizumab
in recurrent cervical cancer was published (ClinicalTrials.org identifier
NCT00548418). Although the study significantly improved mPFS (7.1
months) and mOS (13.2 months), grade 3/4 toxicity was common (throm-
bocytopaenia 82%, leukopaenia 74%, and anaemia 63%) and most patients
(78%) required unanticipated hospital admission.126
The SN38-bearing nanoparticle EZN-2208 (described in Section 8.2.4) has
been shown to inhibit HIF-1a and its downstream targets such as VEGF1 in a
U251 glioma xenograft model.127 The nanoparticle is currently evaluated for
potential HIF-1 inhibition and anti-tumour eﬀects in combination with
bevacizumab in patients with refractory tumours (ClinicalTrials.org identi-
fier NCT01251926).
Combining radiotherapy with HIF-1a inhibition is another frontier under
investigation. Inhibition and knockdown of both HIF-1a and HIF-2a in-
creased tumour sensitivity to radiotherapy.96 A meta-analysis study of more
than 4800 patients connected hypoxic modification of radiotherapy and
improved therapeutic benefit in patients with head and neck cancer.128
Janssen et al. synthesized an RGD-peptide (described in Section 8.2.2)
labeled with radioactive Yttrium-90 (90Y) to target the avb3 integrins on the
endothelium associated with OVCAR-3 ovarian tumour xenografts. The
radiolabeled peptide showed eﬀective tumour tissue penetration and
delayed tumour growth.129 A similar approach used RGD-peptide labelled
with 90Y and Indium-111 (111In).130 Other studies demonstrated that HPMA-
based nanoparticles (described in Section 8.2.3) could be tagged with 90Y
and conjugated to RGD-peptides.131 A combination of short-range and long-
range particle emitters has been suggested. In this way, emitted alpha par-
ticles may have a stronger impact on angiogenesis-associated endothelial
cells, while emitted beta particles are ideal for solid tumour irradiation.132
8.6 CRLX101
CRLX101 (Cerulean Pharma Inc., Cambridge, MA, USA) is a nanopharma-
ceutical composed of 20-(S)-CPT conjugated to a linear, cyclodextrin-
PEG-based polymer (CDP). The polymer–drug conjugate self-assembles into
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soluble nanoparticles composed of several conjugate strands when dissolved
in aqueous solution. The clinical development of CRLX101 is focused on two
unique properties of this nanoparticle, including the ability to increase the
circulatory half-life of CPT and the ability to enhance distribution of CPT
into tumour tissue for prolonged periods with a low plasma concentration of
free CPT.1 Given these unique properties, it was hypothesised that CRLX101
could enhance antitumour activity while avoiding the toxicity observed with
traditional TOP1 inhibitors.
8.6.1 CRLX101 Chemistry
In order to use CRLX101 safely in clinical settings, the de novo design
included key features addressing biocompatibility and low toxicity. The
backbone of this nanoparticle contains b-cyclodextrin (b-CD), which is a
cyclic oligosaccharide consisting of (a-1,4)-linked-a-D-glucopyranose. b-CD is
copolymerised with difunctionalised polyethylene glycol (PEG3400) in order
to give a high molecular weight (450 kDa) polymer. Copolymerising b-CD
with PEG3400 serves two main purposes. First, the high molecular weight of
PEG3400 creates a relatively long distance between reactive groups and thus
minimises the steric hindrance between b-CD molecules in the construction
of polymer chains. Second, PEG3400 plays a key role in avoiding immunor-
ecognition. The large size of CRLX101 also does not allow for first-pass renal
clearance, and thus high levels of circulating nanoparticles are maintained.
The copolymer–CPT conjugate self-assembles into nanoparticles (30–40 nm)
and when dispersed into neutral PBS buﬀer, their zeta potential is
ca. 2mV. Importantly, CPT solubility increased 1000-fold after conjugation.
Although CDP nanoparticles are not biodegradable, they disassemble into
small (B8nm) individual CD polymer strands as soon as CPT is released,
allowing renal clearance to slowly take place. This unique feature of
CRLX101 grants favourable pharmacokinetics with minimal a toxicity profile
(Figure 8.2).1,133,134
Lactone ring stabilisation is a key feature of CRLX101, since CPT is con-
jugated to the polymer in such a way as to protect the lactone ring from
being opened up. CPT is functionalised to form an ester bond at the 20-
hydroxyl group and a glycine linker was used to provide optimal antitumour
eﬃcacy with low toxicity. CPT is conjugated to the carboxylate group on the
linear CD polymer while the lactone ring is maintained (Figure 8.3).6,135
8.6.2 CRLX101 Preclinical Results
Raubitschek et al. at the City of Hope Comprehensive Cancer Center (Duarte,
CA, USA) demonstrated that intravenous administration of CRLX101 was
tolerable and eﬀective against lymphoma models tested, resulting in sig-
nificantly prolonged survival of animals compared to CPT-11. The superior
eﬃcacy of CRLX101 over CPT-11 was demonstrated to result in part in
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sustained and prolonged concentrations of active drug in lymphoma
tumours, which was not achievable with CPT-11.136
Davis et al. at California Institute of Technology (Pasadena, CA, USA),
demonstrated that CRLX101 has excellent tolerability and anticancer
eﬀectiveness in various solid tumour xenografts (NSCLC, SCLC, breast
cancer, colon cancer, pancreatic cancer and Ewing’s sarcoma). In every case,
CRLX101 was demonstrated to be superior to the MTD of CPT-11, and in
some models resulted in complete regressions. Three out of the seven
models tested were resistant to CPT-11, and striking eﬃcacy of CRLX101 was
still observed in these models, demonstrating that CRLX101 can work even in
resistant models.137 In a pharmacokinetic and biodistribution study per-
formed by the same group, intravenous administration of CRLX101 in rats and
tumour-bearing mice resulted in prolonged plasma half-life and enhanced
distribution to tumour tissue when compared to CPT alone. Moreover, the
tumour concentration of active CPT was 160-fold higher after administration
of polymer-bound CPT compared to the administration CPT alone.
Figure 8.2 Polymer self-assembly of CRLX101 nanoparticles. CRLX101 consists of a
potent topoisomerase 1 (TOP1) inhibitor, camptothecin (CPT), conju-
gated to a poly(ethylene) glycol (PEG)–cyclodextrin copolymer via an ester
bond using a glycine linker. CRLX101 self-assembles into B30nm
nanoparticles from 4–5 strands of CPT–copolymer conjugate. Strands
are held together via guest–host complexes between CPT and cyclo-
dextrin. PEG provides ‘‘stealth’’ against immune recognition, resulting
in prolonged circulation of CRLX101. The nanoparticles are large
enough to avoid rapid kidney filtration, but small enough to penetrate
deep into tumours. CPT is released gradually inside tumour cells,
resulting in sustained inhibition of TOP1 and hypoxia-inducible factor
(HIF)-1a. CPT is released via chemical hydrolysis; strands come apart
and are excreted primarily via the kidney. NCE¼new chemical entity.
Figure 8.3 Camptothecin chemical structure.
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These eﬀects likely play a significant role in the enhanced antitumour
activity of CRLX101 when compared to CPT alone or CPT-11.138
Notably, CRLX101 tumour growth inhibition of squamous and non-
squamous NSCLC was superior to approved therapeutic agents such as TPT,
docetaxel (Taxoteres; Aventis), erlotinib (Tarcevas), gemcitabine (Gemzars;
Lilly) and carboplatin (Paraplatins; Bristol-Myers Squibb). Thanks to its
sustained levels within penetrated tumour tissue, CRLX101 inhibited cell
proliferation uniformly. Moreover, CRLX101 eﬀectively inhibited tumour
growth and increased survival in both KRAS-driven and epithelial growth
factor receptor (EGFR)-driven mutation models suggesting that CRLX101
can be eﬀective against drug-resistant NSCLC tumours.139
Furthermore, multi-organ pharmacokinetics and accumulation in tumour
tissue of CRLX101 were investigated using positron emission tomography in
tumour-bearing mice. Tumour vascular permeability was calculated and the
data indicated that the majority of nanoparticles stay intact in circulation
and do not disassemble into individual polymer strands. Histological
measurements using confocal microscopy and transmission electron
microscopy (Figure 8.4) showed that CRLX101 localises within tumour cells
and provides the sink in the tumour for the nanoparticles.140 Similar results
using serial diﬀusion magnetic resonance imaging showed a remarkable
lymphoma tissue penetration and early treatment response in mice treated
with CRLX101 compared to free CPT-11.141
In collaboration with Max Wicha at the University of Michigan and others
at the University of Pennsylvania and Massachusetts General Hospital,
Figure 8.4 Transmission electron microscope image of CRLX101 nanoparticles in a
xenograft tumour cell.
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Eliasof et al. at Cerulean Pharma Inc. demonstrated recently that the
combination of CRLX101 with antiangiogenic therapeutics have synergistic
antitumour properties. CRLX101, through sustained release of its CPT
payload, showed a durable HIF-1a inhibition in multiple human tumour
xenograft models including highly metastatic ovarian tumours. These
promising results encouraged investigators to study the eﬀects of combining
CRLX101 with conventional antiangiogenics. As expected, elevated levels of
HIF-1a associated with bevacizumab, aflibercept (Zaltraps; Sanofi) and
pazopanib treatments were significantly suppressed when combined with
CRLX101. HIF-1a inhibition by CRLX101 was not only sustained for 2 weeks,
but substantial tumour growth inhibition was also achieved. Similar syn-
ergistic eﬀects were observed with radiation therapy in a head and neck
xenograft tumour model. Moreover, confocal microscopic imaging showed
that HIF-1a was translocated into the nucleus after CRLX101 treatment. At
the cancer stem cell level, CRLX101 prevented the bevacizumab-induced
HIF-1a expression and inhibited tumour regrowth of triple negative breast
cancer cells implicating an eﬀective targeting of cancer stem cells.7
8.6.3 CRLX101 Clinical Results
In an initial phase I/IIa dose-finding, safety, and pharmacokinetic study of
CRLX101 in patients with advanced solid tumours, a total of 62 patients were
enrolled and treated (ClinicalTrials.gov identifier NCT00333502). The MTD
was determined to be 15mg m2 on days 1 and 15 of a 28-day cycle.
Haematologic toxicity, including neutropaenia, thrombocytopaenia, an-
aemia, and leucopaenia, was dose-limiting at 18mg m2 administered on a
weekly schedule, and thrombocytopaenia and neutropaenia were also dose-
limiting at 18mg m2 on an every-other-week schedule. In addition, cystitis,
which is an expected toxicity for this drug class, was dose-limiting in a
weekly dosing schedule evaluated in phase I. Hydration before and following
CRLX101 administration was added to the protocol to mitigate the potential
for cystitis. In the phase IIa expansion, 38 patients were enrolled and treated
at the established MTD and the MTD appeared to be safe and well tolerated
for up to six or more treatment cycles, with the majority of adverse events
being grade 1 or 2. The most common of these were fatigue, cystitis, nausea,
anaemia, dysuria, haematuria, and neutropaenia. There were no treatment-
related deaths, and eight patients, including five treated at the MTD,
experienced treatment-related serious adverse events. Three patients
experienced serious infusion-related hypersensitivity reactions, leading to
amendment of the protocol to include pretreatment with a corticosteroid, an
antihistamine, and an H2 antagonist to minimise infusion-related hyper-
sensitivity reactions. Following intravenous administration of CRLX101 at 6,
12, 15, and 18mg m2 in study CRLX-001, systemic plasma exposure to both
polymer-conjugated and unconjugated CPT was observed in all subjects.
Pharmacokinetic analysis demonstrated exposure that is generally pro-
portional to dose and prolonged plasma exposure that is heavily weighted to
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nanoparticle-conjugated CPT. CRLX101 plasma concentrations increased
sharply following intravenous infusion, whereas unconjugated CPT plasma
concentrations increased gradually, consistent with slow release of CPT from
the polymer conjugate. Clearance and volume of distribution values for the
conjugated CPT were dose-independent and suggest this material was
retained within the vasculature and highly perfused tissues. The majority of
subjects receiving CRLX101 every other week at 15mg m2 or 18mg m2 had
measureable levels of unconjugated CPT in plasma at 14 days post-CRLX101
administration, indicating that in order to avoid significant carry-over of
unconjugated plasma CPT from one dose to the next, a dosing interval
greater than 1 week is required. Therefore, all subsequent clinical studies
were performed with an every-other-week schedule.8,142,143
A phase II monotherapy evaluation of CRLX101 include a multi-
site, multi-country comparison of CRLX101 to best supportive care in
NSCLC. Enrolment in this trial is complete and patients remain on study
(ClinicalTrials.gov identifier NCT01380769). In March 2013, Cerulean
Pharma announced that the phase II NSCLC clinical study did not meet its
primary eﬃcacy endpoints and overall survival benefits.144 Multiple
phase II evaluations of CRLX101 are still active to date.
8.7 Conclusion
Preclinical testing of CRLX101 in monotherapy in multiple xenograft models
(NSCLC, squamous NSCLC, KRAS mutant NSCLC, EGFR mutant NSCLC,
SCLC, ovarian cancer, colorectal cancer, gastric cancer, CPT-11-resistant
breast cancer, RCC, pancreatic cancer, and lymphoma) has demonstrated
superiority of CRLX101 over every commercial comparator drug tested. In
these models, the commercial drugs were administered at their respective
optimal dose and dosing schedule andmeasured formedian survival, tumour
shrinkage, and tumour growth delay. In many models CRLX101 achieved
complete tumour eradication and cure, unattainable with the commercial
drugs tested in these models. CRLX101 has also been shown to be a radio-
sensitiser in an animal model of head and neck cancer, suggesting that
CRLX101 may achieve clinical utility in combination with radiotherapy.6,134
It has further been demonstrated in preclinical studies that CRLX101 is a
potent and durable inhibitor of HIF-1a.7,149 The camptothecin family of
compounds (including CPT and TPT) have been described as inhibitors of
HIF-1a in the past. However, the literature suggests that to achieve durable
inhibition of HIF-1a, sustained concentrations of TPT must be delivered to
cells. Due to its short half-life, low tumour targeting, and high toxicities, TPT
cannot eﬀectively achieve durable HIF-1a suppression.125 HIF-1a, which is
up-regulated under hypoxic conditions in the tumour microenvironment,
has recently become a target of increasing interest in cancer research as
it appears to be a master regulator for many key cancer cell survival
pathways.74,76,150 It is hypothesised that simultaneous inhibition of TOP1
and HIF-1a by CRLX101 could lead to notable clinical benefit, particularly
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when the nanopharmaceutical is combined with anti-cancer therapies
such as VEGF receptor inhibitors, which are known to create hypoxia and
up-regulate HIF-1a. In preclinical models, CRLX101 is demonstrated not
only to inhibit HIF-1a, but also to achieve synergistic activity in combination
with bevacizumab and other VEGF receptor inhibitors, including the tyrosine
kinase inhibitor pazopanib and the VEGF trap molecule aflibercept.7
In several animal models, the combination of CRLX101 and leading anti-
angiogenesis drugs demonstrate the following: (1) HIF-1a protein expression
in each case is significantly up-regulated in the presence of each of the
tested anti-angiogenesis drugs; (2) HIF-1a protein expression is significantly
down-regulated when exposed to a low dose of CRLX101; (3) when CRLX101
is combined with anti-angiogenesis drugs, HIF-1a protein expression is
down-regulated compared to control, confirming that the CRLX101 down-
regulation can counteract the up-regulation normally produced by these
anti-angiogenesis drugs; and (4) the combination of a low dose of CRLX101
with anti-angiogenesis drugs is synergistic, resulting in markedly longer
animal survival than either drug by itself.7,130
Similar results have been observed in the preclinical assessment of
the nanopharmaceutical’s eﬀect on cancer stem cells that cause cancer
heterogeneity, drug resistance and metastases. Findings here include:
(1) pretreatment with CRLX101 leads to a reduction in cancer stem cells
expansion compared to control; (2) pretreatment with bevacizumab
leads to enhanced cancer stem cells expansion compared to control; and
(3) pretreatment with a combination of CRLX101 and bevacizumab leads to
reduced cancer stem cell expansion compared to CRLX101 treatment alone,
demonstrating CRLX101’s ability to overcome the HIF-1a-associated and
undesirable cancer stem cells.149
More than 200 human cancer patients have now been treated with
CRLX101 in phase I/IIa and phase II clinical trials. In addition to the
completed clinical trials, other monotherapy studies of CRLX101 are still
running. They include a multi-site randomised phase II clinical trial of 112
patients comparing CRLX101 monotherapy to TPT in advanced small cell
lung cancer, or SCLC, conducted at the University of Chicago (Chicago, IL,
USA) and at other major medical centres in the USA (ClinicalTrials.gov
identifier NCT01803269). The study objectives are to establish feasibility of
enrolling this advanced patient population, and diﬀerentiate the safety and
eﬃcacy of CRLX101 at 15mg m2 dosed every 2 weeks vs. TPT, the only
approved second-line SCLC agent. The first patient was enrolled in January
2013.145 A multisite single-arm phase II clinical trial in advanced ovarian
cancer patients in monotherapy is conducted at the Massachusetts General
Hospital, Brigham and Women’s Hospital, Dana–Farber Cancer Center, and
Beth Israel Deaconess Medical Center (Boston, MA, USA) (ClinicalTrials.gov
identifier NCT01652079). The objectives of this trial are to establish activity
worthy of further investigation based on predefined criteria and to confirm
safety and tolerability of CRLX101 at 15mg m2 dosed every 2 weeks in
ovarian cancer patients. The first patient was enrolled in June 2012 and
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enrolment is now complete with patients remaining on study at this time.146
A single-arm phase II pharmacodynamic clinical trial in advanced human
epithelilal growth receptor 2 (HER2)-negative gastric cancer patients at the City
of Hope National Comprehensive Cancer Center (ClinicalTrials.gov identifier
NCT01612546). This study’s objectives are to establish signals of activity in
HER2-negative gastric cancer patients and to utilise sequential tumourbiopsies
to establish diﬀerential nanopharmaceutical tumour penetration. The first
patient was enrolled in December 2012 and enrolment continues.
Combination therapy evaluations of CRLX101 include a single-arm phase
II clinical trial in advanced RCC patients of CRLX101 at 15mg m2 dosed
every 2 weeks in combination with bevacizumab (10mgkg1 every 2 weeks)
conducted at the University of Pennsylvania (Philadelphia, PA, USA)
(ClinicalTrials.gov identifier NCT01625936). After establishing combin-
ability of CRLX101 at the MTD (phase Ib), the objectives for this trial are to
fulfil the predefined eﬃcacy criteria of the combination, supporting further
evaluation of the combination in RCC. The first patient was enrolled in June
2012 and enrolment is continuing. Very recent results showed that ORR was
30% and mPFS was 7.9 months, which is better than benchmarks such as
everolimus (Afinitors; Novartis) (ORR 4%; mPFS 4.7 months or less).147,148
A multisite single-arm phase II clinical trial in advanced ovarian cancer
patients of CRLX101 at 15mg m2 dosed every 2 weeks in combination
therapy with bevacizumab (10mgkg1 every 2 weeks) conducted at the
Massachusetts General Hospital, Brigham and Women’s Hospital, Dana–
Farber Cancer Center, and Beth Israel Deaconess Medical Center. The
objectives of this trial are to establish activity worthy of further investigation
based on pre-defined criteria and to confirm safety and tolerability of
CRLX101 in combination with bevacizumab in patients with ovarian cancer.
A two-stage design is being employed to enrol a maximum of 43 women.
During Stage I, 18 women will be enrolled and if two or fewer achieve
PFS through six cycles of therapy (PFS6), the trial will be terminated.
Otherwise, a stage II trial will enrol 25 additional women and if, ultimately,
eight or more patients achieve PFS6, the combination will be considered
worthy of further investigation. CRLX101 is under investigation in two
combination treatments for relapsed ovarian cancer. A Phase 2 trial of
CRLX101 plus bevacizumab (Avastins) is enrolling patients, and a Phase 1b
trial of CRLX101 plus weekly paclitaxel (Taxol) has enrolled patients.149
An additional clinical trial evaluating CRLX101 in combination with
chemoradiotherapy (CRT) in the neo-adjuvant treatment of rectal cancer is
about to commence enrolment at the University of North Carolina Chapel
Hill and aﬃliated centres in the USA (ClinicalTrials.gov identifier
NCT02010567). Radiotherapy causes DNA strand breaks which, if not
repaired, lead to desired apoptosis of radiated tumour cells. However, cell
repair mechanisms, including TOP1, which re-ligates DNA strand breaks,
can undo the radiation damage to tumour cells, thus interfering with the
desired eﬀects of the radiation therapy. Since TOP1 is instrumental in
repairing radiation-induced DNA single strand breaks, a combinable TOP1
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inhibitor is hypothesised to be eﬀective as a radiosensitiser. In fact, com-
binations of CPT-11 and CRT have shown synergy, raising pathological
complete response rates in this setting across various trials. However, the
toxicity of CPT-11 prevents its addition to this treatment regimen. CRLX101
in combination with radiotherapy in a head and neck cancer animal model
demonstrates notable synergy and radiosensitivity. In addition, hypoxia is a
by-product of radiotherapy and there is a well-documented role of hypoxia-
mediated HIF-1a induced up-regulation in the induction of resistance to
radiotherapy. Accordingly, it is hypothesised that CRLX101, building on both
its anti-TOP1 and anti-HIF-1a activity, as well as its favourable safety profile,
oﬀers strong potential as an add-on drug to standard of care CRT in
neoadjuvant rectal cancer. This open-label, single-arm phase Ib/II study is
designed to identify the MTD/recommended phase II dose of CRLX101
administered in combination with capecitabine-based CRT and to detect
signals of increased eﬃcacy over CRT alone. The trial is designed to enrol up
to 53 patients, with a primary endpoint of pathological complete response
and secondary endpoints of disease-free survival and mOS.7,149
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